key: cord-0791051-4npkok58
authors: Joshi, Rajendra P.; Gebauer, Niklas W. A.; Bontha, Mridula; Khazaieli, Mercedeh; James, Rhema M.; Brown, Ben; Kumar, Neeraj
title: 3D-Scaffold: Deep Learning Framework to Generate 3D Coordinates of Drug-like Molecules with Desired Scaffolds
date: 2021-06-03
journal: bioRxiv
DOI: 10.1101/2021.06.02.446845
sha: 1e5c6af9b5526bf75c7e2e31373f466165f262aa
doc_id: 791051
cord_uid: 4npkok58

The prerequisite of therapeutic drug design is to identify novel molecules with desired biophysical and biochemical properties. Deep generative models have demonstrated their ability to find such molecules by exploring a huge chemical space efficiently. An effective way to obtain molecules with desired target properties is the preservation of critical scaffolds in the generation process. To this end, we propose a domain aware generative framework called 3D-Scaffold that takes 3D coordinates of the desired scaffold as an input and generates 3D coordinates of novel therapeutic candidates as an output while always preserving the desired scaffolds in generated structures. We show that our framework generates predominantly valid, unique, novel, and experimentally synthesizable molecules that have drug-like properties similar to the molecules in the training set. Using domain specific datasets, we generate covalent and non-covalent antiviral inhibitors. To measure the success of our framework in generating therapeutic candidates, generated structures were subjected to high throughput virtual screening via docking simulations, which shows favorable interaction against SARS-CoV-2 main protease and non-structural protein endoribonuclease (NSP15) targets. Most importantly, our model performs well with relatively small volumes of training data and generalizes to new scaffolds, making it applicable to other domains.

The COVID-19 pandemic, caused by SARS-CoV-2, posed a serious challenge to the public health worldwide. 1 With the aim to address such challenges in developing lead candidates against different diseases, it is necessary to have a disease aware generative model that quickly generates effective therapeutics from the unknown and massive chemical space and could be tested with cell based assay screening.

The discovery and development of a new therapeutic is a long, expensive, and risky process that sometime takes many years before clinical approval. One of the challenges in drug design is to find small molecules with desired functionalities. 2 This is a daunting task with conventional methods, which has slowed down the discovery of high impact molecules for diverse applications. 3 The huge chemical space (10 60 ) of molecules still remains unexplored. [4] [5] [6] Recently, with the rise of deep learning models, several approaches to efficiently explore the astronomically large chemical space have been proposed. The majority of existing approaches focus mainly on de-novo drug design using variational auto-encoders, generative adversarial networks, or reinforcement learning generating molecules mainly in the form of SMILES strings. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] An alternate and robust way to find drug-like molecules is by generating molecules with desired functional groups, core structures, or scaffolds. 19, 20 Such fragments play an important role in determining the functionalities of generated molecules, thus making tuning of properties more flexible. Moreover, molecules with certain scaffolds are likely to have desired interactions with a given protein target as a drug. Scaffold-based approaches allow to incorporate such prior knowledge in the generation process in order to increase the chances of obtaining molecules with desired properties compared to simply generating molecules from scratch. Several approaches have been proposed recently to generate therapeutic candidates building on the core structures. [20] [21] [22] [23] Some of these methods are constrained to certain definitions of scaffolds (e.g. Murcko 24 scaffolds) or do not guarantee that the desired scaffold is always preserved during molecule generation while others do not generalize well for new scaffolds. 21, 23 To the best of our knowledge, none of the existing approaches focuses on generating 3D coordinates of drug-like molecules that can be directly tested against the protein target via computational and experimental screening. However, 3D coordinates of generated molecules are required for physics-based simulations as well as for robust graph-based predictive models for modeling the properties. Moreover, these molecules can be directly used for high throughput virtual screening through structure based docking against the proteins to determine their affinity and efficacy as drugs against a particular disease. Consequently, we believe that 3D molecule generation will accelerate the hit identification and lead optimization for drug discovery and development.

In this work, we propose a deep learning framework called 3D-Scaffold that can generate 3D coordinates of therapeutic candidates given a desired scaffold. It is guaranteed that 100% of the generated molecules contain the desired scaffold and the model generalizes well to previously unknown scaffolds not included in the training data. Our current framework is different from existing scaffold-based approaches for multiple reasons: (I) In contrast to existing approaches, which generate SMILES strings or molecular graphs, our model generates 3D coordinates of the molecules with a given core structure; (II) It works equally well for any type of scaffold definition including BM, cyclic skeletons, or side chains provided SMILES strings exist for the desired scaffolds; (III) Our model is transferable to generate molecules with novel scaffolds where the model is not trained on; (IV) Without constraining the model directly on desired properties, our model can generate molecules with properties similar to the training set.

A few issues arise when constructing physics informed machine learning approaches based on 3D nuclear coordinates in contrast to more abstract molecule representations such as strings or molecular graphs. 25 The coordinate representation is not invariant to rotation, translation, and indexing of atoms while most properties of interest (e.g. the potential energy or the logP score) are invariant to these transformations or change equivariantly (e.g.

atomic forces rotate and translate with the coordinates). The G-SchNet 26 neural network architecture used in our 3D-Scaffold framework systematically obeys these constraints by design. This allow our model to extract features from the coordinates that capture local symmetries and are invariant to rotation, translation, and indexing of the input coordinates.

Furthermore, the distributions it predicts for atom positions equivariantly rotate and translate with respect to the coordinates. Most importantly, we show that our framework designs reasonable molecules even with small training datasets due to the robust architecture of the underlying model. By training it on limited, already known and drug-like molecules, we aim to generate more and previously unseen novel candidates with desired scaffolds that can be synthesized, which ultimately will contribute towards accelerating the discovery of therapeutic drugs.

In this contribution, we applied our 3D-Scaffold for de-novo discovery of molecules specifically tailored to bind with given SARS-Cov-2 diseases targets. Our methodology is exemplified by the task of designing antiviral candidates to target SARS-CoV-2 related proteins.

Using carefully curated covalent and non-covalent antiviral datasets, we were able to constrain the generation space for domain aware deep generative framework to generate novel covalent and non-covalent inhibitor candidates. Properties of generated molecules are com-pared with the molecules in the training set. Generated 3D-coordinates of molecules were further examined for their efficacy as antiviral inhibitors against SARS-COV-2 main protease (Mpro) and a SARS-CoV-2 non-structural protein endoribonuclease (NSP15).

The 3D-Scaffold framework is based on an autoregressive, generative deep neural network named G-SchNet, 26, 27 which builds molecular structures from scratch by iteratively placing one atom after another in 3D space, respecting global and local symmetries by design. The neural network uses SchNet for feature extraction, 28-31 a state-of-the-art predictive model that can predict several quantum mechanical properties of small molecules with benchmark chemical accuracy. In 3D-Scaffold, instead of starting from scratch, molecules are build around a desired scaffold.

From a computational perspective, the neural network used in our framework for denovo therapeutic candidate design is broken down into two major blocks: feature learning and atom placement as shown in Figure 1 . In the feature learning block, embedding and interaction layers are used to extract and update rotationally and translationally invariant atom-wise features that capture the chemical environment of an unfinished molecule. Here, the neural network utilizes continuous-filter convolution layers as a means to learn robust representations of molecules starting only from positions of atoms and corresponding nuclear charges. In the atom placement block, the extracted features are used to predict distributions for the type of next atom and its 3D coordinates, where the latter distribution is constructed from predictions of pairwise distances between the next atom and all preceding atoms. In order to do the actual placement of the next atom in 3D space, a distribution on a small grid with candidate positions focused on one of the preceding atoms is constructed from the predicted pairwise distances. The whole procedure is repeated successively in order to build a complete molecule with desired scaffold: after the type and position of the next atom has been sampled from the predicted distributions, new atom-wise features incorporating the added atom are extracted in the feature learning block and then used to place the following atom with the atom placement block.

The generation process is aided by two auxiliary tokens with unique, artificial types, namely the origin and focus tokens. At each generation step, one of the already placed atoms is uniformly randomly chosen as focus token. The origin token, in contrast, stays fixed throughout the whole generation procedure. In previous work with G-SchNet by Gebauer et al. 26 , the origin token marks the center of mass of molecules. In our 3D-Scaffold framework, however, we instead use it to mark the center of mass of the scaffold that is the starting point of the generation procedure. At each step, the unplaced neighbour of the focus token that is closest to the origin token is supposed to be sampled. This means that while the structure grows around the center of mass of the resulting molecule in the previous G-SchNet Table 1 .

The model is trained end-to-end with backpropagation using the ground truth types and pairwise distances of atoms in training data molecules split into sequential atom placement steps as described in the pseudo code. At each training step, the model predicts the type of the next atom and its distances to all preceding atoms. The distributions predicted by the model are discrete: the type distribution contains a probability value for each atom type occurring in the training dataset and the stop type and the distance distributions cover distances between 0Å and 15Å in 300 equally spaced bins. At any step, let Z next be the ground truth type of the next atom andp Znext type the probability that the model assigns to that type at the current step. Then, we use negative log-likelihood as the loss for the type prediction:

For the loss on distance predictions, we use the cross-entropy between true and predicted distances:

with Gaussian expanded ground truth distances

Here r next is the ground truth position of the next atom, r j is the position of an already placed atom, N is the number of preceding atoms, γ determines the width of the expansions, B are the 300 binned distances between 0Å and 15Å, andp b j is the probability that the model assigns for the distance between r j and r next to fall into distance bin b ∈ B at the current step. In steps where the ground truth type is the stop type, the loss on distance predictions is set to zero as no distances are predicted. Descriptions about the hyper-parameters used in this work is provided in SI.

Therapeutic candidates interact with target proteins either by forming a covalent bond or non-covalently with non bonding interactions. Depending on the kind of interaction, they are known as covalent or non-covalent drug candidates. The focus of our study is to develop 

compute probabilities of grid positions r from distance probabilities next position ← sample(p(r i )) sample position of next atom from computed 3d grid distribution M ← M ∪ {(next type, next position)} Add sampled atom to molecule A ← A ∪ {(next type, next position)} Add sampled atom to set of available atoms del M max atoms atoms are placed but not all of them marked as finished, thus discard the molecule a general framework capable of producing both covalent and non-covalent novel therapeutic candidates with specific scaffolds, so we performed experiments for two different datasets.

First, we performed experiments on covalent inhibitors data (hereafter called covalent dataset) taken from multiple sources. 32, 33 For the covalent dataset, we used ∼4000 candidates from a database of FDA approved drugs 32 

Despite tremendous effort, COVID-19 lacks effective therapeutics. As of now, no antiviral drugs were developed against the closely related coronavirus, SARS-CoV-1 or MERS-CoV, regardless of previous zoonotic outbreaks. 38 To identify starting points for such therapeutics, our focus is to develop a domain informed ML framework to generate covalent electrophiles and non-covalent inhibitor candidates against the SARS-CoV-2 main protease (Mpro) and SARS-CoV-2 non-structural protein endoribonuclease (NSP15), two main viral proteases essential for viral replication. Most of the therapeutic candidates for SARS-CoV-2 have been taken from existing databases to screen against the target proteins. However, it is challenging to generate novel yet target specific molecules knowing the functionality and scaffold that can lead to high potency and efficacy.

Using the covalent antiviral dataset, we first trained the model to generate molecules with 6 different scaffolds that are common electrophilic warheads for different drug applications. The validity of generated molecules is examined by converting generated 3D coordinates into canonical SMILES strings using the xyz2mol script from the Jensen group, 39,40 which relies on Rdkit. 34 The conversion could also be done using only Rdkit or other open source tools like Open Babel but they are less reliable when determining bond orders during conversion. We then used the sanitize functionality of Rdkit to examine the validity of thus obtained SMILES strings. Alternatively, the validity of generated molecules can be measured by performing physics based simulations such as density functional theory. But due to enormous computational cost required to perform such calculations on thousands of generated molecules, we resort to empirical approaches for the same. To examine the novelty of generated molecules, we compared the Rdkit topological fingerprint similarity of the molecules in training set and generated set. The uniqueness metric is determined similarly by using molecular fingerprints. In addition, to further authenticates the performance of our model in generating valid and synthesizable molecules, we also query the MCULE database 37 for generated molecules to check how many already exist in the MCULE dataset. The performance of our model in terms of these metrics is listed in Table 2 .

The performance of our model is similar to existing scaffold-based generative models in terms of generating valid, unique and novel molecules. For all the scaffolds in the covalent dataset, our model performs similarly well, with on average 92% uniqueness among the generated molecules. 81% of generated molecules are valid and ∼100% are novel. These metrics remain similar even for the molecules generated using a novel scaffold (piperazine) as starting point, thus demonstrating the transferrability of our model to scaffolds not in the training set. Compared to the existing generative models in the literature, our model shows superior performance in generating unique and novel molecules, while the percentage of valid molecules generated is in general slightly lower than for other generative models.

We however note that these models were trained on different datasets, making a direct comparison of the reported numbers difficult. Moreover, the performance of our model is especially promising when one takes into account the relatively small amount of training data used (4000) compared to cited models from the literature which were trained on larger training sets. Training our model on larger training sets might further improve the reported statistics. In addition, compared to ours, models from the literature were trained to generate relatively small molecules with the QM9 dataset. When querying the MCULE database, we found that some of the molecules generated for each scaffold are already known and available in the database, demonstrating the success of our model in generating synthesizable molecules. This also holds for the molecules generated with the novel scaffold piperazines.

An important goal of our work is to generate novel molecules with drug-like properties while retaining desired scaffolds. To this end, we do not directly condition molecule generation on the desired properties but instead constrain it to the generation of molecules with desired scaffolds. We expect that this will indirectly constrain the properties, as well. with most generative models. For the logP metric (see Figure 3 (c)), similar distributions are observed between generated and training molecules. We were able to generate both lipophilic as well as hydrophilic compounds as indicated by positive and negative logP, respectively, with the former category being the majority, similar to the molecules in the training set. This again indicates that our model is generating novel molecules with properties similar to the training set. From the QED distribution plot (Figure 3(b) ), we see that the majority (60%) of the molecules have a QED score greater than 0.5, with a good chunk of molecules being close to 1 as evident from the peaks of probability distribution curves around 0.9. Minor discrepancies between the properties of generated molecules and the training set may be due to the lack of directly constrained property optimization in our work. Although our model generates molecules with desired properties, it would be interesting to see its performance when explicitly constraining the desired property range. However, this is beyond the scope of our current work and is kept aside for future work. Figure 3 : Probability density plots of SA score, logP, and QED for molecules in the training set as well as generated set for each functional group. Solid lines correspond to metrics of data in the generated set, whereas dashed lines of same color correspond to molecules in the training set.

We further analyzed the diversity of molecules using heatmaps of the Tanimoto coefficient between molecules within the training set (Figure 4(a) ) and within the generated set ( Figure   4 (b)). The tanimoto coefficient is a measure of the similarity of molecules. The heatmap

shows that the training set we use is quite diverse as evident by the many green spots (low similarity). A similar heatmap is observed for the generated set, showing that generated molecules are quite different from each other, while predominantly maintaining similar properties (as discussed before). We also note that our model generates diverse molecules in terms of their size, i.e. the number of atoms, while always preserving the given scaffolds.

To check the transferability of our model to generate valid molecules for functional groups that are not in training set, we generated 2000 molecules with "Piperazine" as the starting building block. Generated molecules are checked against the MCULE databases to see if any of the generated molecules are already known. We found that nearly 50 of the molecules generated are available in the MCULE database. This shows the capacity of our model to generate valid, synthesizable molecules even for novel scaffolds. The distribution plot for the SA, logP, and QED of the molecules generated for piperazine is included in Figure 3 .

It shows that the properties of molecules generated follow similar distributions as for other functional groups.

We visualize representative generated molecules that we also found in the MCULE database with corresponding SA score, QED, and logP values along with the corresponding MCULE ids in Figure 5 . Overall, our results show that our model constrained to generating molecules with desired scaffolds indirectly also successfully constrains the properties. Despite the significant variation in the amount of training data for each scaffold, our model consistently generates valid, unique, novel, and experimentally synthesizable molecules with desired drug-like properties for each scaffold within and outside of the training set.

Finally, as a proof of concept application for generated molecules, we docked them against main protease (Mpro). Mpro is the key enzyme of SARS-CoV-2 that gets the maximum attention because of its ability to trigger viral replication and transcription. Significant effort has been made since the rapid rise of SARS-CoV-2 worldwide to find therapeutic candidates/vaccines that have desired activity against its protein. Most of the early efforts were focused on drug repurposing using already known drug molecules. For future pandemic events, it is possible that an effective drug molecule for repurposing is not yet known. In those scenarios, models that generate novel molecules with certain functionalities as proposed here will be an efficient alternative. First step for such generated molecules is to examine their efficacy against the target protein using docking simulations. Docking simulations use empirical approaches to determine the favorable/unfavorable binding of ligands with target proteins and numerically rank them using a docking score.

For our molecular docking simulations we utilized the AutoDock for Flexible Receptors (ADFR) package. 42 Ligands were covalently bound to Cystine-145 of the target protein (PDB ID: 6WQF), which is part of a catalytic dyad formed with Hystine-41. We compared the docking score of generated molecules against the training molecules in the covalent dataset which is shown in Figure 6 . A larger magnitude of the docking score implies higher favorability for the docking process. We found that generated molecules show similar docking performance when compared to the molecules in the training covalent dataset as illustrated in the violin plots and the corresponding mean docking score noted in the labels of the xaxis. For the majority of scaffolds, including the novel scaffold piperazines and the three scaffolds that make up 95% of the training data, the generated molecules on average show higher affinity for docking against the Mpro-target protein than molecules in the covalent dataset. The only scaffolds that have a smaller mean docking score compared to the training molecules are maleamides and pyrodines with docking scores of 8.96 and 8.64, respectively.

With the goal of generating non-covalent inhibitors for SAR-Cov-2 targets, we trained our model on the non-covalent dataset using Murcko scaffolds. The training data consist of 36k molecules with 10k unique scaffolds. The performance of our model trained for generating non-covalent inhibitors is similar ( This provide us an interesting target to optimize the Exebryl-1 hit based on 3D-Scaffold framework with better activity and antiviral properties. Our goal is to lead optimization together with in silico molecular docking calculations onto the crystal structure of NSP15.

As a test case example, we generated non-covalent inhibitors for the SAR-CoV-2 nonstructural protein endoribonuclease (NSP15) target (PDB ID: 6XDH) by optimizing Exebryl-1 based compounds. 43 Exebryl-1 has experimentally been found to be active 43 against NSP15 from high-throughput assay screening from drug and lead repurposing libraries. Our goal is to modify and generate more active compounds against the NSP15 target by building molecules on top of Murcko scaffolds of the Exebryl-1 molecule. When examining the structure-activity relationship, some of such generated molecules (see Figure 7) show good binding-activity against the NSP15 target. Moreover, these molecules are easily synthesizable (low SA scores) and have desired drug likeliness (large QED values). Generated molecules from our work that showed high activity against NSP15 from docking and molecular dynamics simulations are further being investigated by our experimental collaborators. Figure 7 : Exebryl-1 and representative generated molecules from our 3D-Scaffold framework with high binding affinity against NSP15 protein-target. For each molecule, we list the SA score, QED, logP, binding affinity, and fingerprint similarity (labelled sim in figure) with respect to experimentally known NSP15 inhibitor Exebryl-1. The scaffold used for optimization is highlighted in red in generated molecules.

In this report, we developed a generative framework that can generate 3D coordinates of therapeutic candidates with any desired scaffold. The model is trained end-to-end incorporating robust atomistic representation learning techniques and generates 3D coordinates from the learned probability distributions of atom types and the pairwise distances. Due to starting the sequential atom-by-atom generation scheme of our framework from a given scaffold, the desired scaffold is 100 % guaranteed in the generated 3D coordinates. We use covalent and non-covalent antiviral datasets to optimally narrow the search towards novel compounds with therapeutic significance that are reasonable to design as covalent and non-covalent inhibitors. We show that our model generates predominantly valid, unique, and novel molecules that have therapeutic drug-like properties similar to the molecules in the training set. The success of our framework lies in generating synthesizable molecules with desired properties without directly constraining on the target properties. Moreover, it performs well for relatively small volumes of training data and generalizes equally well for generating molecules with a new scaffold, which demonstrates the transferability of the proposed framework.

Our framework offers the advantage that the generated 3D-coordinates of molecules can be directly used for further simulations such as DFT, MD, or docking calculations in contrast to SMILES or graph based models where empirical approaches are used to generate 3D

coordinates. As an application, the 3D coordinates of generated molecules from our work were examined for their interaction against the Mpro and NSP15 targets of SARS-CoV-2 using docking simulations. Our results show that generated molecules have favorable interaction against the target protein similar to the molecules in the training set. This holds true for novel scaffolds as well. Although we used our framework to generate covalent and non-covalent inhibitors in this work, our model in principle can be used to generates any kind of molecules with desired scaffolds making it applicable to many domains. We believe that the robust performance of our model on relatively small data sets and its generalization on new scaffolds provides an efficient and flexible way of generating new molecules while simultaneously optimizing the functionalities by constraining the types of scaffolds included.

Further improvement in the performance of the 3D-Scaffold framework may be observed by generating molecules while also explicitly constraining on the target properties or by generating molecules with more than one critical scaffold. 

The COVID-19 pandemic -from great challenge to unique opportunity: Perspective. Annals of Medicine and Surgery

Advancing Drug Discovery via Artificial Intelligence

An overview of drug discovery and development

Estimation of the size of drug-like chemical space based on GDB-17 data

PubChem Substance and Compound databases

Exploring chemical compound space with quantum-based machine learning

Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules

Miguel Hernández-Lobato

Aspuru-Guzik, A. Objective-Reinforced Generative Adversarial Networks (ORGAN) for Sequence Generation Models

Syntax-Directed Variational Autoencoder for Structured Data

Learning a Generative Model for Validity in Complex Discrete Structures

Generating focused molecule libraries for drug discovery with recurrent neural networks

Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks

Deep Reinforcement Learning for de-novo Drug Design

Molecular generative model based on conditional variational autoencoder for de novo molecular design

Application of Generative Autoencoder in De Novo Molecular Design

Generative Recurrent Networks for De Novo Drug Design

Artificial Intelligence based Autonomous Molecular Design for Medical Therapeutic: A Perspective

Structure-Based Drug Discovery

ScaffoldGraph: an open-source library for the generation and analysis of molecular scaffold networks and scaffold trees

Scaffold-based molecular design with a graph generative model

SMILES-based deep generative scaffold decorator for de-novo drug design

DeepScaffold: A Comprehensive Tool for Scaffold-Based De Novo Drug Discovery Using Deep Learning

The Properties of Known Drugs. 1. Molecular Frameworks

Fast and accurate modeling of molecular atomization energies with machine learning

Symmetry-adapted generation of 3d point sets for the targeted discovery of molecules

Generating equilibrium molecules with deep neural networks

SchNetPack: A Deep Learning Toolbox For Atomistic Systems

Quantumchemical insights from deep tensor neural networks

SchNet: A continuous-filter convolutional neural network for modeling quantum interactions

SchNet -A deep learning architecture for molecules and materials

Zinc database

Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94

BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology

a public web service for drug discovery

Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment

Universal Structure Conversion Method for Organic Molecules: From Atomic Connectivity to Three-Dimensional Geometry

MolGAN: An implicit generative model for small molecular graphs

AutoDockFR: Advances in Protein-Ligand Docking with Explicitly Specified Binding Site Flexibility

High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity

Codes used for this work are available at https://gitlab.pnnl.gov/computational_data_ science/ml/3d_scaffolds.